IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v21y2003i1p49-60.html
   My bibliography  Save this article

Potential Costs and Effects of the National Service Framework for Coronary Heart Disease in the UK

Author

Listed:
  • Venanzio Vella

Abstract

Objective: To estimate the costs and effect of implementing the National Service Framework for Coronary Heart Disease (CHD) in the UK. Design: Decision trees were built on the results from randomised controlled trials on improving coronary revascularisation. All costs were presented in UK pounds (1997 values). Patients: Each year 6600 new patients with CHD are expected to require revascularisation in the UK. Interventions: The new patients would be equally divided into those undergoing coronary artery bypass grafting (CABG) and those undergoing a percutaneous coronary intervention (PCI) i.e., percutaneous transluminal angioplasty (PCTA). PTCA could be administered with or without abciximab (a glycoprotein IIb/IIIa receptor antagonist), stent, or stent plus abciximab (stent+). Results: CABG/stent alone has an incremental cost of more than £115 489 per additional quality-adjusted life-year (QALY) gained compared with CABG/PTCA+. This high incremental cost is not attractive because if CABG/stent would be added to abciximab(CABG/stent+) its incremental cost-effectiveness ratio would be £2529 per extra QALY compared with CABG/stent. Therefore, the debate should not be limited to the issue of stents but it should focus on the need for administering abciximab in addition to stent. The 5-year direct costs of implementing such a strategy in the UK is expected to be £50.6 million (1997 values). Conclusions: Abciximab and probably any glycoprotein IIb/IIIa receptor antagonists should be added to any PCI, especially if stents are used. Copyright Adis International Limited 2003

Suggested Citation

  • Venanzio Vella, 2003. "Potential Costs and Effects of the National Service Framework for Coronary Heart Disease in the UK," PharmacoEconomics, Springer, vol. 21(1), pages 49-60, January.
    • Handle: RePEc:spr:pharme:v:21:y:2003:i:1:p:49-60
    DOI: 10.2165/00019053-200321010-00004
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200321010-00004
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200321010-00004?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:21:y:2003:i:1:p:49-60. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.